{
    "nct_id": "NCT03463408",
    "official_title": "Pilot Study of Neoadjuvant Dual Checkpoint Blockade with Concurrent Radiation in Resectable Soft Tissue Sarcoma",
    "inclusion_criteria": "* Diagnosed with biopsy-proven soft-tissue sarcoma with confirmatory pathology review at University of Rochester Medical Center (URMC)\n* 18 years or older.\n* Able to provide informed consent.\n* Resectable disease per surgical evaluation.\n* Neoadjuvant/preoperative radiotherapy has been recommended\n* Intermediate to high grade sarcoma on biopsy, tumor > 5 cm in size by imaging\n* Willing to have blood draws for flow cytometry and Serametrix analysis.\n* Willing to receive neoadjuvant radiation therapy and subsequent surgical resection.\n* Patients with known human immunodeficiency virus (HIV) are eligible if the lymphocytes > 350 CD4+ cells and no detectable viral load.\n* Women of childbearing potential (defined as any woman, who 1) has not undergone tubal ligation, a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months or has had menses at any time in the preceding 24 consecutive months):\n\n  * Must not be pregnant or nursing\n  * Must have a negative pregnancy test done within 7 days prior to registration as well as within 72 hrs. prior to receiving first dose of study medication\n  * Women of childbearing potential must use at least two other accepted and highly-effective methods of contraception and/or agree to abstain from sexual intercourse for at least 5 months after the last dose of nivolumab and/or ipilimumab.\n  * Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n* Sexually active males must use at least two other accepted and highly-effective methods of contraception and/or agree to abstain from sexual intercourse for at least 7 months after the last dose of nivolumab and/or ipilimumab\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Gastrointestinal stromal tumor, dermatofibrosarcoma protuberans, rhabdomyosarcoma, Ewing's sarcoma, low-grade sarcomas, osteosarcoma subtypes\n* History of radiation to the affected area\n* Evidence of metastatic disease prior to treatment\n* Any history of prior therapy with ipilimumab or nivolumab, or any agent targeting PD-1, PD-L1 or CTLA-4.\n* History of any the following:\n\n  * Active known or suspected autoimmune disease\n  * Active autoimmune colitis\n  * Autoimmune pan hypopituitarism\n  * Autoimmune adrenal insufficiency\n  * Known active hepatitis B or C\n  * Known active pulmonary disease with hypoxia defined as:\n* Oxygen saturation < 85% on room air or\n* Oxygen saturation < 88% despite supplemental oxygen\n* No systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration.\n* Second active malignancy, not including localized basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with a history of other malignancies are eligible if they have been continuously disease-free for > 3 years prior to the time of registration.\n* Absolute neutrophil count (ANC) <= 1,500/mm^3\n* Platelet count <= 100,000/mm^3\n* AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) => 2 x upper limit of normal (ULN)\n* Thyroid stimulating hormone (TSH) outside of normal limits; supplementation is acceptable to achieve a TSH within normal limits; in patients with abnormal TSH if free T4 is normal and patient is clinically euthyroid, patient is eligible.\n* Life expectancy under 5 years.",
    "miscellaneous_criteria": ""
}